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Abstract
Immunity contributes to arterial inflammation during atherosclerosis. Oxidized low-density lipoproteins induce an
autoimmune response characterized by specific antibodies and immune complexes in atherosclerotic patients. We
hypothesize that specific Fcc receptors for IgG constant region participate in atherogenesis by regulating the inflammatory
state of lesional macrophages. In vivo we examined the role of activating Fcc receptors in atherosclerosis progression using
bone marrow transplantation from mice deficient in c-chain (the common signaling subunit of activating Fcc receptors) to
hyperlipidemic mice. Hematopoietic deficiency of Fcc receptors significantly reduced atherosclerotic lesion size, which was
associated with decreased number of macrophages and T lymphocytes, and increased T regulatory cell function. Lesions of
Fcc receptor deficient mice exhibited increased plaque stability, as evidenced by higher collagen and smooth muscle cell
content and decreased apoptosis. These effects were independent of changes in serum lipids and antibody response to
oxidized low-density lipoproteins. Activating Fcc receptor deficiency reduced pro-inflammatory gene expression, nuclear
factor-kB activity, and M1 macrophages at the lesion site, while increasing anti-inflammatory genes and M2 macrophages.
The decreased inflammation in the lesions was mirrored by a reduced number of classical inflammatory monocytes in
blood. In vitro, lack of activating Fcc receptors attenuated foam cell formation, oxidative stress and pro-inflammatory gene
expression, and increased M2-associated genes in murine macrophages. Our study demonstrates that activating Fcc
receptors influence the macrophage phenotypic balance in the artery wall of atherosclerotic mice and suggests that
modulation of Fcc receptor-mediated inflammatory responses could effectively suppress atherosclerosis.
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Introduction
Atherosclerosis is considered not only merely a lipid disorder,
but also a chronic inflammatory disease of the arterial wall [1].
Innate (monocyte-derived macrophages) and adaptive (T lympho-
cytes) immune response both contribute to the arterial inflamma-
tion that characterizes atherosclerosis, a dynamic process also
involving different cell types such as endothelial cells and vascular
smooth muscle cells (SMC). Early atherosclerotic lesions are
characterized by the presence of foam cells in the intima as a result
of macrophage infiltration and lipid internalization. Foam cells
secrete pro-inflammatory cytokines thereby amplifying the initial
inflammatory response. Sustained inflammation then results in
lesion progression, degradation of the extracellular matrix causing
plaque destabilization and rupture [2].
Diversity and plasticity are hallmarks of monocyte/macrophage
system, which are reflected in plaque formation and progression
[3]. Two major monocyte subsets termed classical (Ly6Chigh) and
non-classical (Ly6Clow) function as control switches of the immune
system and maintain the balance between pro- and anti-
inflammatory activities [4]. Different macrophage subtypes (M1,
classically activated and pro-inflammatory; M2, anti-inflammatory
and tissue repair) also participate in inflammatory processes during
atherogenesis, being M1 the predominant phenotype in human
and murine atheromata. M1 macrophage markers include
inducible nitric oxide synthase (NOS), interleukin (IL)-12, tumor
necrosis factor-a (TNF-a), interferon-c (IFN-c), and arginase (Arg)
2, whereas enhanced expression of IL-4, IL-10, Arg1, mannose
receptor and galactose type C-type lectin associate with M2
phenotype [3–5].
Antigen-antibody immune complexes (IC) are implicated in
many autoimmune and inflammatory diseases. Autoimmunity is
also an independent risk factor of atherosclerosis and cardiovas-
cular disease associated mortality [6]. Autoantibodies against
oxidized low-density lipoproteins (oxLDL) have been found in
blood and lesions of atherosclerotic patients and are considered
cardiovascular biomarkers [7,8]. IgG autoantibodies have a pro-
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atherogenic effect through the formation of oxLDL-containing IC
and cell activation via specific IgG Fc receptors (FccR) [6,9]. In
mice, four FccR classes have been identified (FccRI/CD64,
FccRII/CD32, FccRIII/CD16, and FccRIV/CD16-2) differing
by their distinct affinity for IgG subclasses, cellular distributions,
and effector functions [10,11]. Activating FccR (I, III and IV)
associate with the common c-chain that contains the intracellular
tyrosine-based activating motif, and upon ligand binding they
stimulate phagocytosis, oxidative burst, cytokine release, and
antibody-dependent cell-mediated cytotoxicity. In contrast, en-
gagement of inhibitory FccRIIB abrogates inflammatory responses
and instead regulates alternative signaling cascades [10,11].
Evidence indicates the involvement of IC and FccR in
atherogenesis. Several FccR have been detected in human
atherosclerotic lesions [12], and differential FccR expression on
peripheral blood monocytes associates with severe atherosclerosis
[13–15]. In hypercholesterolemic mice, gene deficiency in single
or multiple FccR regulates atherogenesis [16–19] and renal injury
[20]. Accordingly, immunomodulation based on FccR blockade is
proposed as an alternative therapy [21].
It has been previously proven that bone marrow transplantation
using knockout mice is a useful approach to study the contribution
of hematopoietic cells to atherogenesis, and that hematopoietic-
originating macrophages are the major type of cells recruited to
the vascular wall during atherosclerotic lesion formation [22].
Accordingly, the present study investigates the effect of activating
FccR deficiency within bone marrow-derived cells on the
development of atherosclerotic plaques in the Apolipoprotein E
knockout (ApoE2/2) mouse model. For this purpose, we used
donor marrow from double deficient mice in ApoE and c-chain
[16], the common subunit necessary for assembly, cell-surface
localization, and functionality of activating FccR (types I, III and
IV). We therefore hypothesize that functional deficiency in
activating FccR attenuates atherosclerosis progression in mice by
reducing the inflammatory state of monocytes/macrophages.
Methods
Ethics Statement
The housing and care of animals and all the procedures carried
out in this study were strictly in accordance with the Directive
2010/63/EU of the European Parliament and were approved by
the Institutional Animal Care and Use Committees of Autonoma
University and IIS-Fundacion Jimenez Diaz.
Bone Marrow Transplantation
Male ApoE2/2 (C57BL/6 background, Jackson Laboratory,
Bar Harbour, ME) and double deficient mice in c-chain and ApoE
(c2/2ApoE2/2) [16] were used in these studies. Donor mice were
anesthetized by 2% isoflurane inhalation and sacrificed by cervical
dislocation. Bone marrow cells were collected from tibias and
femurs of donor mice and treated with Gay’s solution to exclude
red blood cell contamination for protection against vascular
(thrombotic) injury, as previously described [23]. Recipient mice
(ApoE2/2, 14-weeks-old) were exposed to 8–9 Gy of radiation
and then received 5–106106 bone marrow cells from donors
(ApoE2/2 and c2/2ApoE2/2) by intravenous injection into the
tail vein to generate the respective bone marrow chimeras (ARA,
n= 17; cARA, n= 22). Since donors and transplanted mice had
the same genetic background, there were no symptoms of graft-
versus-host disease in any of them. Mice were monitored daily for
survival (Kaplan-Meier method), and after a 4 week recovery
under sterile conditions, they were placed on a Western diet
(21.2% fat, 0.15% cholesterol, 17.3% protein; Harlan Labs,
Madison, WI) for 10 weeks. Mouse genotype was analyzed by
PCR in purified genomic DNA from peripheral blood. Murine c-
chain primer sequences [16,23]: exon3 (59-
GGAATTCGCTGCCTTTCGGACCTGGAT-39), exon2 (59-
GGAATTCGATGCTGTCCTGTTTTTGTA-39) and neo c-
chain in which exon2 was replaced (59-GCCAACGC-
TATGTCCTGATAG-39). Murine ApoE primer sequences [24]:
sense21 (59- GCCTAGCCGAGGGAGGACCG-39), antisense20
(59-TGTGACTTGGGAGCTCTGCAGC-39), and neo19 (59-
GCCGCCCCGACTGCATCT-39). Wild-type (WT) mice were
used as control genotype (c+/+ApoE+/+).
Mouse Sacrifice and Tissue Preparation
Mice were anesthetized by intraperitoneal injection of ketamine
(100 mg/kg) and xylazine (15 mg/kg). The adequacy of anesthesia
and animal safety were monitored by standard methods (pedal
withdrawal, palpebral reflexes, respiration, and skin/mucous
membrane color) prior to all experimental procedures. Blood
was obtained through retro-orbital puncture. Hearts were perfused
with sterile saline via the left ventricle at physiological pressure.
Spleens and thoraco-abdominal aortas were preserved in liquid N2
and processed for mRNA analysis [25].
Histological Analysis
Aortic sinus was embedded in OCT and serially cryosectioned
(8 mm sections covering <1200 mm from valve leaflets). Every
third slide was stained with oil-red-O/hematoxylin for morpho-
metric quantification of maximum plaque area [26]. Leukocytes
were detected by immunostaining with rat anti-mouse Moma2
(macrophage marker; Serotec, Oxford, UK), CD3 and CD4 (T
cell markers; BD Biosciences, Erembodegem, Belgium) antibodies,
followed by biotinylated secondary antibody (Amersham, Buck-
inghamshire, UK), avidin-biotin horseradish peroxidase detection
(Dako, Glostrup, Denmark) and hematoxylin counterstain. Mac-
rophage phenotypes and T regulatory cells were analyzed by
immunofluorescence using Arg2 (M1 marker; Santa Cruz), Arg1
(M2 marker; Santa Cruz), Mac-3 (total macrophage marker; BD
Biosciences), and Forkhead box p3 (Foxp3; BD Biosciences)
antibodies, followed by respective secondary antibodies (Alexa
Fluor 568 and 488; Invitrogen, Carlsbad, CA) and nuclear
counterstain (49,6-diamidino-2-phenylindole). Proliferating cells
and chemokine expression were detected by immunoperoxidase
using proliferating cell nuclear antigen (PCNA) and CCL2
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), respec-
tively. Apoptosis was determined using the Tunel method
(ApopTag Peroxidase Kit, Millipore, Billerica, MA). SMC were
detected by direct immunofluorescence with a-smooth muscle
actin antibody (Cy3 conjugated; Sigma Chemicals, St. Louis,
MO). Negative controls were run in parallel with the omission of
primary antibodies. Picrosirius red staining was performed for
analysis of collagen content by measuring birefringence to plane-
polarized light. Activated NF-kB was detected by in situ
Southwestern histochemistry using digoxigenin-labeled consensus
probe, followed by alkaline phosphatase conjugated anti-digox-
igenin antibody (Amersham), as described [27]. Positive staining
was quantified using Image Pro-Plus 4.5.0.29 (Media Cybernetics,
Bethesda, MD) and expressed as percentage of total plaque area or
number of cells per lesion area [25,28].
Biochemistry and Flow Cytometry
Total serum cholesterol and triglyceride concentrations were
measured using standard enzymatic methods. Total serum
immunoglobulins were measured by sandwich ELISA using
specific antibodies recognizing mouse IgM, IgG, IgG1, IgG2a/c
Macrophage Fcc Receptors in Atherosclerosis
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and IgG3 (BD Biosciences, San Diego, CA). Specific anti-oxLDL
immunoglobulins were determined by ELISA using microtitration
plates coated with native LDL and oxLDL (1 mg/mL), as
previously described [20]. FACS analysis of mouse blood
leukocytes was performed with the following fluorochrome-
conjugated antibodies and appropriated isotype controls: CD45-
FITC, CD3e-PE-Cy7, CD4-PE, CD8a-FITC and CD19-PE form
BD Biosciences; CD115-PE and Ly6C-APC from eBioscience
(San Diego, CA). Data were acquired using a BD FACS Canto II
Flow Cytometer and analyzed with BD FACSDiva software (BD
Biosciences).
Isolation of Murine Macrophages
Peritoneal macrophages were harvested by peritoneal lavage of
anesthetized mice (ApoE2/2, c2/2ApoE2/2 and WT), then
plated and allowed to adhere for 2 h. After extensive washing with
PBS to eliminate non-attached cells, macrophages were lysed and
processed for RNA and protein expression analysis. For foam cell
counting, peritoneal macrophages on coverslips were incubated
for 6 h in DMEM containing oxLDL alone (25 mg/mL) and
oxLDL-containing IC (IgG1 and IgG2 subclasses, 1:0.5 ratio of
oxLDL to IgG), then fixed with 4% paraformaldehyde and stained
with oil-red-O/hematoxylin. The total cell and foam cell (.8 lipid
droplets) numbers were counted, and the percentage of foam cells
was calculated. Bone marrow-derived cells were differentiated for
7 days in DMEM containing 10% FBS, 100 U/mL penicillin,
100 mg/mL streptomycin, 2 mM L-glutamine (Life Technologies,
Rockville, MD), and supplemented with 10% L929-cell condi-
tioned medium as a source of macrophage colony stimulating
factor. Differentiated macrophages were serum-starved for 12 h
before addition of soluble IC (75 mg/mL) for different time
periods. The oxLDL-IC and soluble IC used in this study were
prepared as previously described [16,20,29].
mRNA Expression Analysis
Total RNA from aorta, spleen and macrophages was extracted
with TRIzol reagent (Invitrogen) as described [25,28]. Expression
of target genes was analyzed by real-time quantitative PCR
(Applied Biosystem, Foster City, CA) and normalized to house-
keeping 18S transcripts.
Protein Expression Analysis
Macrophages were homogenized in 10 mM Tris-HCl pH 7.4
containing 150 mM NaCl, 1% Triton X-100, 0.5% NP-40, 1 mM
EDTA, 1 mM EGTA, 0.2 mM Na3VO4, 10 mM NaF, 0.2 mM
PMSF, and protease inhibitor cocktail. Cytosolic proteins (25 mg)
were resolved on SDS-PAGE gels, transferred onto polyvinylidene
difluoride membranes and immunoblotted with Arg2 and Arg1
antibodies (0.4 mg/mL) followed by peroxidase-conjugated sec-
ondary antibody (Amersham). After visualizing by enhanced
chemiluminescence system (Amersham), membranes were re-
blotted for b-actin (Sigma) as loading control. Immunoblots were
quantified using Quantity One software (Bio-Rad, Hercules, CA).
CCL2/CCL5 concentrations in macrophage supernatants were
analyzed using mouse ELISA kits (R&D Systems, Minneapolis,
MN).
Lucigenin Chemiluminescence Assay
Macrophages were resuspended in 200 mL modified Krebs-
Ringer-HEPES buffer (10 mM HEPES pH 7.4, 119 mM NaCl,
4.7 mM KCl, 1.2 mMMgCl2, 2.5 mM CaCl2, 1.2 mM KH2PO4,
25 mM NaHCO3, and 2 mM glucose), transferred to Ro¨hren
tubes and then 5 mM lucigenin and 100 mM NADPH (Sigma)
were added. Chemiluminescence was measured with a Luminom-
eter (Berthold Technologies, Bad Wildbad, Germany) by counting
the photon emission at 20-s intervals over 10 min. Superoxide
production was expressed as relative chemiluminescence units per
mg of cell protein [20].
Statistical Analysis
Data are presented as mean6SEM. Differences across exper-
imental groups were analyzed for statistical significance by
unpaired Student’s t test or by one-way ANOVA followed by
post-hoc Bonferroni pairwise comparison using GraphPad Prism 5
(GraphPad Software, La Joya, CA). Values of P,0.05 were
considered significant.
Results
Reconstitution with c2/2ApoE2/2 Bone Marrow Reduces
Atherosclerotic Lesion Size
To examine whether an activating FccR-dependent mechanism
in macrophages accounts for increased atherosclerosis in vivo, we
performed bone marrow transplantation experiments. Irradiated
ApoE2/2 mice were reconstituted with bone marrow derived
from either c2/2ApoE2/2 double deficient mice (cARA group)
or control ApoE2/2 donor mice (ARA group), and after
recovering were fed on atherogenic diet for 10 weeks. Chimerism
in cARA group was confirmed by genomic PCR analysis of
peripheral blood (Figure 1A). Successful engraftment of marrow
occurred in more than 90% of animals. After recovery, over 90%
of blood cells were from donor origin and blood immune cell
composition was similar between genotypes. Furthermore, survival
of both chimera groups remained similar along the study (log-rank
test, P.0.05; Figure 1B).
The size and extent of atherosclerotic lesion was quantified by
morphometry after oil-red-O/hematoxylin staining. Aortic lesions
in chimeric ApoE2/2 recipient mice receiving bone marrow cells
from c2/2ApoE2/2 donors were 2.5-fold smaller by area
(P,0.0001) than mice transplanted with ApoE2/2 bone marrow
(Figure 1, C–E). Moreover, quantification of lipid content in
plaques (oil-red-O stained area) revealed a reduced lipid accumu-
lation in cARA compared with ARA mice (% of plaque area:
16.163.1 versus 50.1612.3; P=0.002; not shown). Both groups
had comparable body weight and total cholesterol and triglyceride
levels at the end of the study period (Table 1). These findings
suggest that FccRs in bone marrow-derived cells are critical for
lesion development in this model.
Attenuated Inflammation and Enhanced Stability in
Atherosclerotic Plaques of FccR Deficient Mice
Immunohistochemical analysis of cross-sections adjacent to
sections of maximum plaque area showed a significantly decreased
accumulation of monocytes/macrophages (Moma2+) and T
lymphocytes (CD3+ and CD4+) at the atherosclerotic lesions of
cARA mice (Figure 2, A–C), while the number of T regulatory
cells (Foxp3+) was increased (Figure 2D). Regression analysis
showed correlation of lesion area with Moma2, CD3, CD4 and
Foxp3 staining in the experimental groups (Pearson r values: 0.87,
0.67, 0.82 and 20.51; P,0.01; not shown), thus indicating a more
inflammatory component in larger lesions.
To assess plaque vulnerability, aortic lesions were analyzed for
collagen (picrosirius red staining) and SMC (a-actin immunoflu-
orescence), which are important stabilizing components of the
plaque. Atherosclerotic plaques in cARA mice exhibited a
modest, but significant increase in total collagen and SMC
content (Figure 3A) as compared with those of control ARA mice
Macrophage Fcc Receptors in Atherosclerosis
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(% of total plaque area: picrosirius red, 20.961.9 versus 12.263.6,
P=0.04; a-actin, 18.562.1 versus 12.861.4, P=0.03). Interest-
ingly, the relative ratio of collagen to lipids (picrosirius red/oil-red-
O) and SMC to macrophages (a-actin/Moma2) did markedly
increase in the cARA group (Figure 3B). The higher collagen and
SMC content and the lower lipid and leukocyte content in lesions
of FccR deficient mice are consistent with a more stable plaque
phenotype. There was also a significant reduction in lesional
apoptosis (Tunel staining) in cARA mice, whereas the number of
proliferating cells (PCNA staining) was not different between the
two groups (Figure 3, C and D).
Inflammatory Mediator Expression and Immunoglobulin
Isotype Distribution in Transplanted Mice
Lesions of cARA mice showed significantly less protein
expression of macrophage chemokine CCL2 than controls
(Figure 4A). Likewise, Southwestern histochemistry showed an
attenuated activity of NF-kB, the transcription factor that
regulates many pro-inflammatory and pro-atherosclerotic genes
Figure 1. Reconstitution with c2/2ApoE2/2 marrow attenuates diet-induced lesion progression in mice. Irradiated ApoE2/2 mice were
reconstituted with bone marrow from ApoE2/2 and c2/2ApoE2/2mice and after 4 weeks were fed on atherogenic diet for 10 weeks. (A) PCR analysis
of ApoE and c-chain genes in genomic DNA isolated from donor (ApoE2/2 and c2/2ApoE2/2), transplanted (ARA and cARA), and control (WT)
mice. (B) Kaplan-Meier curves showing survival rate of transplanted mice (log-rank test, P=0.562). (C) Representative photomicrographs
(magnification x40) of aortic root sections stained with oil-red-O/hematoxylin. (D) Quantification of maximum lesion area in the aortic root of ARA
(filled circles, n = 17) and cARA (open circles, n = 22) mice. (E) Average of lesion area throughout the studied region in each group. Measurements are
expressed as mean6SEM. *P,0.01 versus ARA group.
doi:10.1371/journal.pone.0066754.g001
Table 1. Physiologic measurements in transplanted ApoE2/2
mice.
DonorRrecipient Body weight (g) Cholesterol Triglycerides
combination (n) Initial Final (mg/dL) (mg/dL)
ARA (17) 18.960.2 24.860.6 482611 9563
cARA (22) 18.360.3 24.260.5 475615 9365
Reconstitution with bone marrow cells from c-chain deficient mice did not alter
body weight and serum lipid levels. Results (mean6SEM) were compared by
two-tailed, unpaired t test with Welch’s correction. No significant difference was
observed between the experimental groups.
doi:10.1371/journal.pone.0066754.t001
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(Figure 4B). Levels of CCL2 and NF-kB correlate with lesion size
(Pearson r = 0.91 and 0.85; P,0.0001; not shown), and macro-
phage content (Pearson r = 0.78 and 0.74; P,0.0001; not shown)
in the experimental groups.
Quantitative real-time PCR analysis on RNA from aortic tissues
revealed considerable differences in the gene expression of
chemokine CCL2 and the intracellular adhesion molecule-1
(ICAM-1) in cARA mice (% decrease versus control ARA
group: 4464 and 4268, respectively; P,0.04; Figure 4C). FccR
deficiency also significantly reduced the aortic expression levels of
the signature cytokines for Th1 (TNF-a and IFN-c) and Th2 (IL-4)
responses (% decrease: 4868, 5568 and 40610, respectively;
Figure 4C), although their relative proportion did not change
between ARA and cARA groups (TNF-a/IL-4 ratio: 2.360.3
versus 2.160.3; IFN-c/IL-4 ratio: 2.160.4 versus 1.960.3;
P.0.05). Analysis of spleen samples demonstrated similar expres-
sion of Th1/Th2 cytokines (IFN-c/IL-4 ratio: ARA, 2.160.4;
cARA 1.960.3; P.0.05), and overexpression of T regulatory cell-
associated transcription factor Foxp3 in FccR deficient mice
(Figure 4D).
Changes in the adaptive immune response were assessed by
measuring serum antibody titers to oxLDL epitopes. Total
antibody isotypes (IgM and IgG) and IgG subclasses (1, 2a/c
and 3) were not different between the experimental groups
(Figure 5, A and B). Interestingly, oxLDL-specific IgG response,
but not IgM, was increased in cARA mice relative to ARA
controls (Figure 5C). Determination of anti-oxLDL IgG subclasses
revealed significant differences in IgG1 and IgG2a/c levels in
cARA mice (Figure 5D). However, the relative ratio of IgG2a/c
(Th1 response) to IgG1 (Th2 response) did not change between the
groups (1.260.1 versus 1.360.1; P.0.05), thus indicating no
apparent Th1/Th2 bias.
Figure 2. FccR deficiency alters leukocyte content in atherosclerotic plaques. Histological analysis of macrophages (A) and T lymphocytes
(C–D) in aortic lesions from ARA (n= 17) and cARA (n= 18) mice. Representative images showing Moma2 (A), CD3 (B) and CD4 (C)
immunoperoxidase staining (magnification x200) and Foxp3 (D) immunofluorescence (red, with arrows; magnification x400). Quantifications of
positive cells per lesion area are indicated in the right panels. Results are expressed as mean6SEM.
doi:10.1371/journal.pone.0066754.g002
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FccR Deficiency Affects Monocyte/macrophage
Activation State in Atherosclerotic Mice
Our findings thus far indicate that FccR deficiency reduced the
accumulation of inflammatory cells in atherosclerotic plaque. We
then examined whether FccR deficiency influenced the leukocyte
count or subset frequency in peripheral blood using flow cytometry
(Table 2). Blood counts for total leukocyte number and subgroups
(B cells, T cells and monocytes) revealed no differences between
ARA and cARA mice. Interestingly, analysis of monocyte subset
distribution (Ly6Chigh and Ly6Clow) of CD115+-gated monocytes
revealed decreased percentages of Ly6Chigh and increased
percentages of Ly6Clow subsets in cARA group. This resulted in
a significant decrease in the ratio of Ly6Chigh:Ly6Clow monocytes
in FccR deficient mice compared with controls (Table 2), thus
indicating a reduced activation state of circulating monocytes.
To further examine the macrophage phenotype associated with
FccR deficiency in atherosclerotic lesions, the gene expression of
Arg2 and Arg1 isoforms was analyzed to distinguish between the
pro-inflammatory classical M1 and the anti-inflammatory alter-
native M2 response, respectively. Immunofluorescence and gene
expression analysis (Figure 6) revealed that both macrophage
markers are present in atherosclerotic lesions, being Arg2 (M1)
most abundantly expressed in ARA mice, and Arg1 (M2) the
predominant marker in cARA. Furthermore, calculation of
Arg2/Arg1 ratio (average per group: ARA, 2.260.1; cARA,
0.560.1, P,0.0001) and regression analysis (Figure 6C) demon-
strated that higher lesion size correlated with the dominance of
M1 over the M2 macrophage phenotype marker.
FccR Deficiency Prevents Foam Cell Formation and
Inflammatory Responses in Macrophages
Studies in peritoneal macrophages were further performed to
assess lipid accumulation and foam cell formation in atheroscle-
rotic mice. Quantification of oil-red-O staining in resident
peritoneal cells from mice on high-fat diet revealed an increased
number of foam cells in ApoE2/2 as compared with WT
littermates (% macrophage foam cells: WT, 26.161.9; ApoE2/
2, 61.866.4; P=0.01; n = 6) and a decrease in FccR deficient
mice (% macrophage foam cells: 33.065.3, P=0.01 versus
ApoE2/2; n = 6). In other experiments, peritoneal macrophages
from ApoE2/2 and c2/2ApoE2/2 mice on chow diet were
incubated for 6 h in the presence of oxLDL alone and oxLDL-
containing IC. As shown in Figure 7A, foam cell formation was
similarly induced by oxLDL in both cell types. By contrast, foam
cell numbers after oxLDL-IC incubation were significantly
reduced in peritoneal cells from c2/2ApoE2/2 mice versus
ApoE2/2 mice (Figure 7A), despite having equivalent expression
levels of scavenger receptors (SR-A and CD36; Figure 7B). These
results confirm the involvement of FccR in oxLDL-IC uptake and
foam cell formation.
Peritoneal macrophages from FccR deficient mice exhibited a
reduced expression of pro-inflammatory genes (CCL2, TNF-a and
Arg2) and increased expression of M2 response genes (IL-10,
TGF-b and Arg1) (Figure 7C). Accordingly, analysis of Arg2 and
Arg1 protein expression revealed that the relative ratio of M1 to
M2 markers was higher in peritoneal macrophages from ApoE2/2
Figure 3. FccR deficiency increases features of atherosclerotic plaque stability. (A) Representative images showing collagen (picrosirius red
staining) and SMC (a-actin immunofluorescence) content in aortic sections from transplanted mice. Original magnification x100. Dashed lines
highlight the area of atherosclerotic plaque. (B) Quantification of collagen to lipid ratio (picrosirius red area/oil-red-O area) and SMC to macrophages
(Mw) ratio (a-actin area/Moma2 area) in ARA and cARA mice. (C) Detection of apoptosis (Tunel staining) and cell proliferation (PCNA staining) in
plaques. Magnification x200. (D) Quantification of Tunel and PCNA positive cells per lesion area in ARA and cARA mice. Data are the mean6SEM of
n = 12 animals per group.
doi:10.1371/journal.pone.0066754.g003
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mice as compared with WT littermates, and was significantly
reduced by FccR deficiency (Figure 7D).
Further experiments were performed in bone-marrow derived
mouse macrophages. Treatment with soluble IC resulted in a
significant polarization of ApoE2/2 macrophages to the M1-like
phenotype, as evidenced by a predominant Arg2 levels (Figure 8A)
with concomitant increase in other classical activation markers,
including pro-inflammatory cytokines (TNF-a, IL-6 and IFN-c;
Figure 8A) and chemokines (CCL2 and CCL5; Figure 8C). In
contrast, IC failed to prime c2/2ApoE2/2 macrophages to the
pro-inflammatory phenotype, as evidenced by reduced expression
levels of M1 markers (Figure 8, A and C) and increased M2
response genes (Figure 8B). Furthermore, macrophages from FccR
deficient mice exhibited reduced oxidative stress in response to IC
stimulation, as measured by NADPH oxidase-dependent super-
oxide production (Figure 8D).
Discussion
The present study demonstrates a key role for macrophage
FccR in initiation and progression of vascular lesions in
experimental atherosclerosis. Our bone marrow transplantation
studies show that hematopoietic gene deficiency in c-chain, the
common signaling subunit of activating FccR (types I, III and IV),
is sufficient to limit atheroma plaque formation in mice. The
underlying mechanisms are independent of serum lipids and Th1/
Th2 changes. Instead, our data indicate that FccR deficiency
reduces circulating inflammatory monocytes, impairs foam cell
formation and skews the distribution of macrophage population
within the plaque towards the anti-inflammatory phenotype.
Inflammation is recognized as a major contributor to athero-
genesis through adverse effects on lipoprotein metabolism and
arterial wall biology. Accumulating evidence indicates that both
humoral and cell-mediated pro-atherogenic immunity against
altered self-antigens generated by hypercholesterolemia (such as
oxLDL particles) play a predominant role in the atherogenic
process [6]. Clinical studies have demonstrated a positive
association between the degree of established atherosclerosis and
antibody levels to oxLDL, mainly IgM and IgG isotypes [7,8].
High production of IgM and IgG anti-oxLDL antibodies has also
been observed in hypercholesterolemic mice [30,31]. It has been
proposed that atheroprotective IgM contributes to maintain low
plasma levels of oxLDL and blocks the uptake of oxLDL by
lesional macrophages, thereby preventing the oxLDL accumula-
tion and foam cell formation [32,33]. On the other hand, IgG
Figure 4. Hematopoietic FccR deficiency reduces inflammation in atherosclerotic mice. CCL2 protein expression (A) and NF-kB nuclear
activity (B) in aortic sections from transplanted mice. Representative micrographs (magnification x200) and quantification of positive staining per
lesion area are shown. Gene expression levels in aorta (C) and spleen (D) of ARA and cARA mice were measured by real-time PCR. Values were
normalized to 18S and expressed as arbitrary units (a.u.). Data are mean6SEM of total number of animals per group. *P,0.03 versus ARA group.
doi:10.1371/journal.pone.0066754.g004
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antibodies are pro-atherogenic through the formation of oxLDL-
containing IC and induction of FccR-mediated inflammatory
responses in resident and infiltrating cells [6,34]. In fact, FccR is
the most important macrophage receptor involved in the clearance
of oxLDL-IC [9]. In the current study, despite the difference in
atherosclerosis severity, the IgM anti-oxLDL response remained
unchanged in mice reconstituted with c2/2ApoE2/2 bone
marrow. Interestingly, the IgG antibodies to oxLDL increased,
probably due to impaired phagocytic activity in FccR deficient
cells. In mouse models, severe hypercholesterolemia is associated
with an antibody switch from Th1 (IgG2a) to Th2 (IgG1) response
[30], whereas B cell depletion reduces the production of anti-
oxLDL antibodies and limits atherosclerosis development [35]. As
the concentrations of both IgG subclasses were enhanced in the
serum of c2/2ApoE2/2 transplanted mice, we can consider that,
instead of a polyclonal activation of B cells, the two Th1- and Th2-
type T cells are indeed involved in the antibody response against
oxLDL. Although this antibody pattern suggests a more
pronounced Th1 and Th2 immune response in FccR deficient
mice, our analysis of the Th1/Th2 ratio did not substantiate
systemic changes in Th cell composition. Furthermore, flow
cytometry analysis revealed similar content of blood leukocytes
and subgroups (B cells, T cells and monocytes) in both groups of
transplanted mice. Interestingly, lack of FccR declined the number
of circulating Ly6Chigh monocytes, the classical inflammatory
subset predominant in hypercholesterolemic mice [36] that is
preferentially adhered to activated endothelium, accumulated in
lesions, and locally differentiated into macrophages [4,37]. Our
observations confirm these previous reports highlighting the
prominent role of classical monocytes in atherogenesis and as
source for lesional macrophages [36,37], and suggest that a
reduced monocyte activation state is involved in the atheropro-
tective effect of FccR deficiency.
The coordinate expression of activating and inhibitory FccR
ensures the homeostasis of IC-driven inflammatory responses. In
fact, gene deficiency in activating FccR is associated with
diminished inflammation in response to IC, while severe
inflammation was observed following deletion of inhibitory
FccRIIB [11,38]. In atherosclerotic mice, FccRIII deficiency
caused a reduction in aortic lesion size [17], whereas FccRIIB
deletion aggravates the atherosclerotic process [18]. Our early
study demonstrated that mice lacking c-chain associated FccR
developed less atherosclerotic plaques characterized by a reduction
in leukocyte content and inflammatory mediators [16]. Recently,
Figure 5. Immunoglobulin isotype distribution in transplanted mice. Sera from ARA (filled symbols, n = 7) and cARA (open symbols, n = 7)
transplanted mice were analyzed for total (A, B) and oxLDL-specific autoantibodies (C, D). IgG and IgM isotypes (A, C) and IgG subclasses (B, D) were
determined by ELISA using specific antibodies as indicated in Methods. Values are expressed as absorbance units at l=450 nm.
doi:10.1371/journal.pone.0066754.g005
Table 2. Flow cytometry of blood leukocyte populations in
mice.
Cell type Marker ARA cARA
Leukocytes CD45 82.6610.3 80.067.0
T lymphocytes CD3 40.064.9 46.167.8
CD4 15.662.5 19.366.7
CD8 4.661.2 5.961.9
B lymphocytes CD19 33.965.7 31.967.2
Monocytes CD115 17.662.5 18.165.0
Ly6Chigh:Ly6Clow 4.860.3 2.460.2*
Quantitative analysis shows significant decrease in the ratio of Ly6Chigh:Ly6Clow
among CD115+ monocytes of FccR deficient mice. Numbers indicating
percentage of positive cells are means 6 SEM of 7 animals. *P= 0.03 versus
ARA.
doi:10.1371/journal.pone.0066754.t002
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Ng et al. [19] reported an increased generation of circulating T
regulatory cells with a concomitant decrease in Th17 cells in c-
chain deficient mice. The current data complement these previous
immunological changes and also directly address the functional
role of FccR activation on resident and recruited monocytes/
macrophages during atherosclerosis promotion. We cannot,
however, rule out that FccR on other cells also modulate plaque
development and progression, since bone marrow transplantation
reconstitutes more than monocytes/macrophages [22]. In fact,
hematopoietic stem cells are able to differentiate into endothelial
and vascular SMC progenitors [39], and bone marrow cells
accumulated in atherosclerotic lesion differentiate into vascular
SMC and foam cells thereby contributing to vascular remodeling
[40]. Moreover, different FccR are found expressed on endothelial
and SMC, which demonstrate pro-atherogenic response to FccR
stimulation in vitro [16,28,41]. Thus, further studies will be needed
to demonstrate conclusively the relative contribution of FccR on
both resident vascular and infiltrating cells in this process.
The presence of oxLDL antibodies and FccR in atheroma
plaques has been clearly demonstrated in patients [12,42]. In
mice, adoptive transfer studies of CD4+ T cells specific to oxLDL
have shown that Th1 cell responses play an important role in
promoting atherosclerosis [43]. Our study demonstrates that
reconstitution with c-chain deficient marrow in mice with
developing atherosclerosis significantly attenuates further progres-
sion without affecting plasma lipid levels. First, the decrease in
atheroma size correlates with a reduced number of T cells and
macrophage foam cells and higher T regulatory cell content in
aortic lesions. This indicates a deficient pro-atherogenic immune
activation in the artery and also a key role of T regulatory cell
function in FccR deficient mice, consistent with previous studies of
the protective effect of T regulatory cells in atherosclerosis
progression [19,44]. Secondly, hematopoietic FccR deficiency
resulted in the development of a lipid-poor collagen-rich
atherosclerotic lesion characterized by higher collagen/lipid and
SMC/macrophage ratios and low apoptosis, thereby suggesting a
more stable plaque phenotype. Because most acute complications
of atherosclerosis are caused by the rupture of an unstable lipid-
rich collagen-poor lesion [1], strategies to modulate activating
FccR may have a beneficial role in slowing lesion progression.
In parallel with the reduction in leukocyte infiltration,
hematopoietic FccR deficiency leads to reduced local expression
of genes involved in leukocyte activation and migration during
atherogenesis [45,46], including adhesion molecule ICAM-1,
chemokine CCL2, pro-atherogenic Th1 cytokines TNF-a and
IFN-c, and Th2 cytokine IL-4. However, and consistent with the
IgG subclass ratios, the relative proportion of Th1/Th2 cytokine
expression in aorta and spleen remained unmodified, thus
discarding either lesional or systemic Th1/Th2 imbalance.
Transcription factor NF-kB is a major regulator of immunoin-
flammatory responses that controls cytokine gene expression and
has a pivotal role in atherogenesis [46]. We have earlier
demonstrated NF-kB activation and target gene expression in
experimental atherosclerosis [25] and also in cultured cells after
FccR cross-linking [16,20,29]. Keeping in line with this, our study
shows that FccR deficiency blunted the activity of NF-kB in cells
of the intima and media, thus indicating that NF-kB’s effect on
inflammation and lipid handling can be regulated by IC in
vascular and infiltrating cells. These data do not exclude a
contribution of systemic inflammatory factors, such as serum
cytokines and C-reactive protein previously shown to be increased
in atherosclerosis [45,47], but suggest that the atherogenic effects
of FccR are mainly mediated via inflamed cells localized in
plaques.
Besides effects on the plaque macrophage content, FccR
deficiency had a dramatic effect on the inflammatory state of
Figure 6. Effect of FccR deficiency on macrophage phenotype in atherosclerotic lesions. (A) Immunofluorescence analysis of total
macrophages (Mac-3; red), and phenotypes M1 and M2 (Arg2 and Arg1, respectively; green) in aortic sections from transplanted mice. Representative
photomicrographs (top panel, magnification x200) and high-magnification images (x400) of the selected regions (squares). (B) Quantification of
Arg2+ and Arg1+ macrophages per lesion area. Values represent the mean6SEM of total number of animals per group. (C) Real-time PCR analysis of
Arg isoforms in aortic tissue. Correlation between Arg2/Arg1 expression and lesion area in ARA (filled circles, n = 16) and cARA (open circles, n = 17)
mice is shown.
doi:10.1371/journal.pone.0066754.g006
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these cells, with a general decrease and increase, respectively, in
markers of M1 (classically activated) and M2 (alternatively
activated or tissue repair) macrophages. Although this classifica-
tion scheme has been considered to be overly simplistic, it has been
a useful start with which to broadly characterize the macrophage
heterogeneity known to occur in many tissues including athero-
sclerotic plaques [3]. Previous works have evaluated the phenotype
of macrophages associated with progression of atherosclerosis in
mice. While early lesions are infiltrated by reparative M2
macrophages, the M1 sub-type appeared and prevailed during
plaque progression [48]. These M1 cells accumulated in damaged
vessel wall are able to secrete many inflammatory cytokines that
amplify Th1 immune response, affect SMC function and
proliferation, and also contribute to lipoprotein oxidation through
the production of reactive oxygen species [4,49]. In our work, the
reduction in plaque lipid content and lesion size was accompanied
by a decrease in infiltrating macrophages and pro-inflammatory
mediators, along with a lower ratio of M1/M2, as determined by
differential expression of Arg isoforms. Macrophage Arg converts
arginine to ornithine and urea and competes directly for substrate
with NOS, and the two isoforms (mitochondrial Arg2 and
cytosolic Arg1) have been evaluated as surrogate markers of M1
and M2 phenotypes during atherosclerotic progression [48,50].
Indeed, classical M1 macrophages in the lesions express Arg2 and
inducible NOS, but not Arg1, while alternatively activated M2
macrophages exclusively express Arg1. In our paper, the
prevalence of M2 marker (Arg1) in aortic lesions from FccR
deficient mice suggests that these smaller lesions contain macro-
phages of anti-inflammatory and tissue repair phenotype and
consequently may be more stable. Concurrently, the pattern of
pro- and anti-inflammatory cytokine expression in isolated
macrophages strongly indicates that FccR deficient macrophages
resemble features of anti-inflammatory M2-like macrophages. It
has been previously reported that IC-stimulated macrophages
more closely resemble M1 than M2 in terms of cytokine profile
and functionality [51]. Furthermore, selective cross-linking of
inhibitory FccRII/CD32, but not activating FccR (CD64 and
CD16) accounts for the induction of CCL1 chemokine in human
monocytes and is linked to M2 activation program [52]. An
additional mechanistic study [53] revealed the involvement of
activating FccR and NF-kB pathway in the polarization of human
monocytes toward pro-inflammatory M1 macrophages by C-
reactive protein. In line with this, our data indicate that the pro-
atherogenic role of activating FccR is related to the pro-
inflammatory and pro-oxidative action on macrophages.
Collectively, our results document a role for activating FccR in
controlling the macrophage phenotypic balance in the artery wall
of atherosclerotic mice. We therefore propose that strategies to
modulate FccR activating/inhibitory balance and effector func-
Figure 7. FccR deficiency inhibits foam cell formation and pro-inflammatory gene expression in peritoneal macrophages. (A)
Macrophages from ApoE2/2 and c2/2ApoE2/2 mice were exposed to oxLDL alone (25 mg/mL) and oxLDL-IC (IgG1 and IgG2, 1:0.5 ratio) for 6 h. Cells
containing oil-red-O stained fat droplets were considered foam cells. Representative images (original magnification x400) and macrophage foam cell
quantification are shown. (B) Real-time PCR analysis of scavenger receptors (CD36 and SR-A) in freshly isolated peritoneal macrophages. Values
corrected by 18S expression are expressed as arbitrary units (a.u.). (C) Expression levels of M1 and M2 response genes in macrophages from WT,
ApoE2/2 and c2/2ApoE2/2 mice. Data are normalized to WT values ( = 1; dashed line). (D) Western blot analysis of Arg isoforms in peritoneal
macrophages from WT, ApoE2/2 and c2/2ApoE2/2mice. Data of densitometry are corrected by loading control (b-actin) and expressed as Arg2/Arg1
ratio. Bars represent the mean6SEM of n = 5–7 animals per group. *P,0.05 versus Basal; # P,0.05 versus ApoE2/2 cells.
doi:10.1371/journal.pone.0066754.g007
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tions could suppress atherosclerosis by regulating macrophage
inflammatory states into the reparative M2 phenotype.
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